PACS Group shares fell over 30% on November 4, 2024, after a Hindenburg Research report alleged the company improperly inflated Medicare revenue through misuse of COVID waivers from 2020 to 2023. The report highlights significant regulatory risks for PACS.
Contact our attorneys for a no-cost case evaluation.